Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy by Antonio Piras et al.
RESEARCH Open Access
Autophagic and lysosomal defects in
human tauopathies: analysis of post-
mortem brain from patients with familial
Alzheimer disease, corticobasal
degeneration and progressive supranuclear
palsy
Antonio Piras1, Ludovic Collin2, Fiona Grüninger2, Caroline Graff1,3 and Annica Rönnbäck1*
Abstract
Introduction: The accumulation of insoluble proteins within neurons and glia cells is a pathological hallmark of
several neurodegenerative diseases. Abnormal aggregation of the microtubule-associated protein tau characterizes
the neuropathology of tauopathies, such as Alzheimer disease (AD), corticobasal degeneration (CBD) and
progressive supranuclear palsy (PSP). An impairment of the lysosomal degradation pathway called macroautophagy,
hereafter referred to as autophagy, could contribute to the accumulation of aggregated proteins. The role of
autophagy in neurodegeneration has been intensively studied in the context of AD but there are few studies in other
tauopathies and it is not known if defects in autophagy is a general feature of tauopathies. In the present study, we
analysed autophagic and lysosomal markers in human post-mortem brain samples from patients with early-onset
familial AD (FAD) with the APP Swedish mutation (APPswe), CBD and PSP and control individuals.
Results: FAD, CBD and PSP patients displayed an increase in LC3-positive vesicles in frontal cortex, indicating an
accumulation of autophagic vesicles. Moreover, using double-immunohistochemistry and in situ proximity ligation
assay, we observed colocalization of hyperphosphorylated tau with the autophagy marker LC3 in FAD, CBD and PSP
patients but not in control individuals. Increased levels of the lysosomal marker LAMP1 was detected in FAD and CBD,
and in addition Cathepsin D was diffusely spread in the cytoplasm in all tauopathies suggesting an impaired lysosomal
integrity.
Conclusion: Taken together, our results indicate an accumulation of autophagic and lysosomal markers in human
brain tissue from patients with primary tauopathies (CBD and PSP) as well as FAD, suggesting a defect of the
autophagosome-lysosome pathway that may contribute to the development of tau pathology.
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Introduction
Abnormal intracellular aggregation and accumulation of
the microtubule-associated protein tau is a common fea-
ture of many neurodegenerative disorders, including
Alzheimer disease (AD), frontotemporal lobar degener-
ation, Pick´s disease, argyrophilic grain disease, cortico-
basal degeneration (CBD) and progressive supranuclear
palsy (PSP) [3]. Collectively, these neurodegenerative
disorders are referred to as tauopathies. Under normal
conditions, tau is predominantly expressed in neuronal
axons where its main function is to promote micro-
tubule assembly and stabilization, which is important for
maintaining axonal transport and neuronal integrity
[45, 60, 69]. The molecular mechanisms leading to
intracellular tau aggregation in AD and other tauopa-
thies are not fully understood, but abnormal post-
translational modifications, such as hyperphosphorylation
and acetylation [20, 47], and impaired degradation of tau
[14] have been suggested.
Two major proteolytic systems contribute to tau deg-
radation, the ubiquitin-proteasome system (UPS) and
the autophagy-lysosome system [50, 52, 67]. The role
of each of these pathways to the turnover of tau is an
area of significant interest [16, 32, 38, 40, 66, 67]. The
major lysosomal degradative pathway in eukaryotic
cells, macroautophagy (hereafter referred to as autoph-
agy), is responsible for degrading long-lived or aggre-
gated proteins and is the principal mechanism for
turning over cellular material too large to be degraded
by the UPS [29, 75, 76]. Autophagy is a highly regu-
lated process that involves the sequestration of cytoplas-
mic cargo, such as aggregated proteins and damaged
organelles, within double-membrane vesicles called
autophagosomes which are typically labelled by the
microtubule-associated protein 1A/1B-light chain 3
(LC3) [23, 29, 30, 72, 76]. In order to achieve degrad-
ation of aggregated proteins in the autophagy-lysosome
system, there must be a successful fusion of the autop-
hagosomes with the lysosomes [17, 18, 29, 36, 73].
Functional autophagy is crucial for neuronal physiology
and loss of autophagy in the central nervous system,
for example by inactivation of key autophagy genes
such as autophagy-related (Atg) proteins 5 (Atg5) or 7
(Atg7) leads to neurodegeneration [22, 31]. In Atg7
knockout mouse brains, there is a significant accumula-
tion of hyperphosphorylated tau suggesting a role of
autophagy in the clearance of pathological tau in adult
neurons [25]. Furthermore, increased accumulation of
autophagic vesicles has been reported in human post-
mortem AD brains and in mouse models of tauopathy
[41, 54, 77]. Constitutive overexpression of mTor,
(mammalian Target of rapamycin), a key negative regu-
lator of the autophagic pathway, prevents activation of
the autophagy pathway and increases the levels of
hyperphosphorylated tau in a cell model of tauopathy
[65]. Conversely, autophagy enhancers like rapamycin
(an mTor inhibitor) or trehalose (an mTor-independent
autophagy activator) can promote the degradation of
insoluble tau in mouse models of tauopathy [9, 56, 61].
Finally, post-translational modifications of tau can
interfere with and impair the clearance mechanisms.
For example, phosphorylation of tau at serine 422 (Tau/
pS422) prevents tau cleavage by caspase-3 at aspartic
acid 421 (D421), precluding tau degradation by the
autophagy-lysosome system [21]. Taken together these
observations suggest that the autophagy-lysosome path-
way plays an important role in the clearance of hyper-
phosphorylated tau. The majority of studies on human
neurodegenerative disease and autophagy have included
patients with Alzheimer disease where both Aβ and tau
aggregations are key features (reviewed in [43, 55]), and
only few studies have focused on other human tauopa-
thies [19, 71]. Thus, in order to address the contribu-
tion of the autophagy-lysosomal system in different
tauopathies, we studied human post-mortem brain
tissue from patients with both tau and Aβ pathology
[familial AD (FAD) cases with the Swedish double-
mutation in the amyloid precursor protein (APPswe)]
as well as brain tissue from patients with a primary
tauopathies in the absence of significant amyloid path-
ology (CBD and PSP). In agreement with previous studies
of sporadic AD cases [42, 51, 54], we found an accumula-
tion of markers of the autophagy-lysosomal pathway in AD
patients with the familial APPswe mutation. In addition,
we showed that the autophagy-lysosomal system is im-
paired in patients with primary tauopathies suggesting that




Human post-mortem brain tissue samples from frontal
cortex were obtained from the Brain Bank at Karolinska
Institutet. Three patients with early onset familial AD
(FAD) caused by the Swedish amyloid precursor protein
gene double-mutation KM670/671NL (APPswe), four
patients with CBD and three patients with PSP as well
as brain tissue from six control subjects (absence of neu-
rodegenerative disease) were included (Table 1).
Immunohistochemistry
Immunohistochemical staining was performed on 5 μm
sections from formalin fixed paraffin embedded (FFPE)
frontal cortex of post-mortem brains. The sections were
deparaffinised and hydrated through xylene and graded
alcohol series. The sections were autoclaved with antigen
retrieval buffer (DV2004, DIVA Decloaker, Biocare Med-
ical) for 30 min at 110 °C (Decloaking Chamber NxGen,
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Biocare Medical). After the temperature decreased to
room temperature (RT), sections were washed with water
for 5 min and then in Tris-Buffered Saline (TBS) + 0.05 %
Tween® 20 (TBS-T) (91414, Sigma-Aldrich). The sections
were incubated in Peroxidase block solution (K4007,
Dako) 5 min at RT to quench the endogenous peroxidase
activity. Sections were then incubated with primary anti-
bodies (Table 2) diluted in Antibody Diluent (S3022,
Dako) for 45 min at RT, followed by 30 min incubation
with EnVision Mouse (K4007, Dako) at RT. The immu-
noreactions were visualized with DAB (K4011, Dako). All
sections were counterstained with haematoxylin for 30 s
and washed in tap water. The sections were washed thor-
oughly in TBS-T between each step. Dehydration was
performed in increasing concentrations of ethanol, cleared
in xylene and mounted with DPX mountant (360294H,
VWR). For every experiment, tissue sections from a control
or a tauopathy-patient were incubated without the primary
antibody to be used as a negative control.
For immunofluorescence staining, all sections were
processed under the same standardized conditions, fol-
lowing the method described above with minor modifi-
cations. After deparaffinization and antigen retrieval, the
sections were blocked with Background Punisher (BP974,
Biocare Medical) for 10 min at RT followed by washing
and incubation with primary antibodies (Table 2) in TBS-
T (overnight 4 °C, humid chamber). After washing in
TBS-T, sections were incubated (1 h at RT) with appro-
priate secondary antibodies [anti-mouse and anti-rabbit
IgG (H + L)] conjugated to Alexa Fluor 546 (A-11003,
Invitrogen) or Alexa Fluor 488 (A-11008, Invitrogen) at
a concentration of 1:500 in TBS-T. After washing in
Table 1 Human brain samples
Case no Age at death (years) Gender (M/F) Age at onset (years) PMI (hours/days) Brain weight (g) Analysis
Ctrl_1 70 M - 18 h 1482 IHC, IF
Ctrl_2 64 F - 5 h 1204 IHC, IF, PLA, WB
Ctrl_3 84 F - 96 h 1210 IHC, IF, PLA
Ctrl_4 59 M - na 1390 IHC, IF, PLA
Ctrl_5 82 F - 9 h 1200 WB
Ctrl_6 80 M - 16 h 1200 WB
APPswe_1 62 M 53 40 h 1024 IHC, IF, PLA, WB
APPswe_2 66 M 61 24 h 1140 IHC, IF, PLA, WB
APPswe_3 56 M 44 24 h 1161 IHC, IF, PLA, WB
CBD_1 80 F 74 8 days 1075 IHC, IF, PLA, WB
CBD_2 69 M 62 66 h ~1000 IHC, IF, PLA
CBD_3 70 M 64 24 h 930 IHC, IF, PLA
CBD_4 67 F 59 48 h 1045 WB
PSP_1 66 F 59 144 h 1490 IHC, IF, PLA
PSP_2 71 F 63 na 1121 IHC, IF, PLA
PSP_3 68 M <66 na 1350 IHC, IF, PLA
PMI post-mortem interval, time from death until autopsy, IHC immunohistochemistry, IF immunofluorescence, PLA proximity ligation assay, WB western blot, na
not available
Table 2 List of primary antibodies
Antigen Supply Reference Clonality Host Dilution Analysis
AT8 Thermo Scientific MN1020 Monoclonal Mouse 1:1000 IHC, PLA
Tau/pS422 Roche - Monoclonal Mouse 1:1000 IF
LC3 Novus Biologicals NB100-2331 Polyclonal Rabbit 1:200 IF PLA
p62/SQSTM1 Santa Cruz sc-25575 Polyclonal Rabbit 1:50 IF
LAMP1 Santa Cruz sc-20011 Monoclonal Mouse 1:200 WB
Cathepsin D (Cat D) Sigma-Aldrich HPA003001 Polyclonal Rabbit 1:500 IF
Cathepsin D (Cat D) Abcam Ab6313 Monoclonal Mouse 1:500 IF
GAPDH Enzo ID4 Monoclonal Mouse 1:2000 WB
IHC immunohistochemistry, IF immunofluorescence, PLA proximity ligation assay, WB western blot
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TBS-T (3 × 10 min) slides were incubated with (or
without) Sudan Black B (199664, Sigma-Aldrich), 5 min
at RT to reduce autofluorescence. Sections were then
washed in TBS-T and incubated with DAPI for 5 min
(D9564, Sigma-Aldrich). After washing in TBS-T,
coverslips were mounted with Vectashield Hard Set (H-
1200, Vector Laboratories) and the slides were stored at
4 °C. Sections from controls and patients were also in-
cubated without primary antibody and used as negative
control. Sections were examined using a laser scanning
confocal microscope (LSM 510 META, ZEISS), and im-
ages were acquired using the same settings (laser inten-
sity, detector gain and amplifier offset).
In situ Proximity Ligation Assay (PLA)
To specifically detect protein interaction (when the pro-
teins are in close proximity <40 nm), PLA analyses were
performed on section from FFPE frontal cortex of hu-
man brain from three patients of each group (Table 1).
Deparaffinization and antigen retrieval were performed
as described above. In situ PLA was performed accord-
ing to the OLINK Bioscience instructions. To reduce
non-specific signals, the sections were incubated with
Blocking solution (82007, OLINK Bioscience) for 30 min
at 37 °C. Sections were then incubated overnight at 4 °C
with two primary antibodies (Table 2) in antibody diluent
solution (82008, OLINK Bioscience) (80–100 μl/section).
For each patient, two negative controls were performed by
omitting one of the two primary antibodies (negative con-
trol 1 and negative control 2). After washing with TBS-T,
sections were incubated with in situ PLA DNA-probes
anti-rabbit PLUS and anti-mouse MINUS (82002 and
82004, OLINK, Bioscience) for 1 h at 37 °C. Ligation solu-
tion was added for 30 min at 37 °C, and washed twice with
washing Buffer A (82047, OLINK, Bioscience). The ampli-
fication solution (92013, Detection reagents Far Red,
OLINK Bioscience) was added for 100 min at 37 °C. Fol-
lowing incubation the sections were washed in Buffer B
(82048, OLINK, Bioscience). The sections were allowed to
dry and mounted with Vectashield Hard Set mounting
medium with DAPI (H-1200, Vector Laboratories). Im-
ages from at least ten different fields of the frontal cortex
for each sample were acquired using a laser scanning
confocal microscope (LSM 510 Meta, ZEISS). Then, the
images were analyzed with DUOLINK Image Tool soft-
ware (OLINK Bioscience), which automatically counts the
number of fluorescent signals (dots) per field. The signal
was calculated as Dots = DotsPLA-(Dotsneg1 + Dotsneg2),
where the DotsPLA is the number of dots of in situ PLA
and Dotsneg1 and Dotsneg2 are respectively the dots ob-
tained from negative control 1 [only primary antibody 1,
anti-tau clone AT8 (pS202/T205)] and negative control 2
(only primary antibody 2, LC3) [62]. Data were expressed
as mean value ± Standard Deviation (S.D.) and ANOVA,
followed by the Dunnett post-hoc test, was used for statis-
tical analysis (IBM SPSS Software). Significance levels of
*p < 0.05, **p < 0.01, *** p < 0.001 were used.
Western blotting
Frozen tissue from frontal cortex (~145 mg/sample) of
human brains from FAD (n = 3), CBD (n = 2) and Control
(n = 3) (Table 1) were homogenized in RIPA buffer (50 mM
Tris pH 7.5; 150 mM NaCl; 0.5 % sodium deoxycholate;
0.1 % SDS; 1 % NP40) containing Benzonase Nuclease
(70664–3, Millipore, 1:1000), Phosphatase and Protease in-
hibitor cocktails (P8340 and P0044, Sigma-Aldrich, 1:100)
on ice. Samples were centrifuged at 7000xg for 10 min at
4 °C. Supernatants were stored at −20 °C.
After determination of the protein content by BCA
protein assay (23227, Thermo Fischer Scientific), homog-
enates (30–50 μg total protein) were separated on
NuPAGE® 12 % Bis-Tris Gels, 1.0 mm, 10 wells
(NP0341, Life Technologies) by electrophoreses in run-
ning buffer MOPS [3-(N-morpholino) propanelsulfonic
acid] (NP0001, Life Technologies) and blotted onto iBlot
Gel Transfer Stacks Nitrocellulose (IB301001, Life Tech-
nologies). The membranes were blocked in 5 % non-fat
milk (70166, Sigma-Aldrich) in TBS-T. Membranes were
incubated overnight at 4 °C with primary antibodies (see
Table 2), washed in TBS-T and then incubated with sec-
ondary species-specific antibodies (NA934 anti-rabbit,
NA931 anti-mouse, GE Healthcare) in TBS-T + 5 %
non-fat milk for 1 h at RT. Blots were visualized with
enhanced chemiluminescence reagent (34076, Pierce).
Images were obtained with a FujiFilm LAS-3000 cam-
era and semiquantitative analysis was performed using
ImageJ software. Data were expressed as mean inten-
sity of an arbitrary unit (AU) ± S.D. and were obtained
from the average of at least 3 replications of the ex-
periment. For quantification of immunoblots, protein
levels were normalized to GAPDH. ANOVA, followed
by the Dunnett post-hoc test, was used to compute
statistical significance and significance levels of *p <
0.05, **p < 0.01, *** p < 0.001 were used.
Results
Characterization of tau pathology in frontal cortex from
patients diagnosed with different tauopathies
Human post-mortem brain tissue from cases with early-
onset FAD, CBD, PSP and control individuals without
neurodegeneration was analysed by immunohistochemis-
try to determine the presence of hyperphosphorylated tau
using two different phospho-tau antibodies: clone AT8
(pS202/T205, Fig. 1) and Tau/pS422 (Additional file 1:
Figure S1). Patients carrying the APPswe mutation showed
extensive tau immunoreactivity in neurofibrillary tangles
(Fig. 1a, large arrow), pretangles (defined by diffuse cyto-
plasmic tau immunoreactivity, Fig. 1a, asterisk), dystrophic
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neurites around amyloid plaques (Fig. 1a, small arrow) and
neuropil threads. All CBD cases showed hyperphosphory-
lated tau in neuronal pretangles (Fig. 1b, asterisk), astro-
cytic plaques (Fig. 1b, #), threads in grey and white matter
and oligodendroglial coiled bodies (data not shown). Tau-
immunoreactive pretangle neurons (Fig. 1c, asterisk), tufted
astrocytes (Fig. 1c, arrowhead) and coiled bodies in oligo-
dendroglia (data not shown) were present in frontal cortex
of the PSP cases. In contrast, no tau immunoreactivity was
detected in the control individuals (Fig. 1d). Our data con-
firmed that hyperphosphorylated tau accumulates in the
frontal cortex of all three patient groups.
Accumulation of p62/SQSTM1 and colocalization with
hyperphosphorylated tau in frontal cortex from cases
with tauopathies
The polyubiquitin-binding protein p62/SQSTM1 is
necessary to target protein aggregates for degradation
via autophagy [6, 57], and/or the ubiquitin-proteasome
system [2, 4, 63]. To investigate whether the protein
clearance was defective in patients with tauopathies, we
analysed the p62/SQSTM1 protein by immunostaining.
Only rare p62/SQSTM1 inclusions were detected in
control brain sections (Fig. 2a, green), while we
observed an intense p62/SQSTM1 immunostaining in
FAD, CBD and PSP (Fig. 2b-d, green), showing that
p62/SQSTM1 accumulates in patients with tauopathies.
Binding of p62/SQSTM1 to hyperphosphorylated tau is
necessary for the clearance of tau as reported in p62-
knockout mice that showed an accumulation of hyper-
phosphorylated tau and neurofibrillary tangles [2].
Therefore we investigated the colocalization of p62/
SQSTM1 and phospho-tau (Tau/pS422, Fig. 2f-h). We
found that p62/SQSTM1 colocalized with hyperpho-
sphorylated tau in neuronal cell bodies (arrowheads in
Fig. 2j, n) and in neuropil threads (asterisks in Fig. 2j, m)
in FAD patients. In CBD patients, an extensive colocali-
zation of p62/SQSTM1 and hyperphosphorylated tau
was found mainly in threads (asterisks in Fig. 2k and high
magnification Fig. 2o). Finally, in PSP patients we found
colocalization of p62/SQSTM1 and hyperphosphorylated
tau both in threads (asterisks in Fig. 2l, p) and in cell
bodies (arrowhead in Fig. 2l, p), similar to what we
observed in FAD patients. Altogether, the accumulation
of p62/SQSTM1 and its colocalization with hyperphory-
lated tau suggest defective protein clearance in tauopathy
patients, which is in accordance with previous studies
[33, 34].
Fig. 1 Tau pathology in frontal cortex as showed with the AT8 antibody. a APPswe mutation carriers show AT8 immunoreactivity in neurofibrillary
tangles (arrow), pretangles (asterisk), neuropil threads and dystrophic neurites around amyloid plaques (small arrow). b AT8 immunohistochemistry
revealed diffuse cytoplasmic tau immunoreactivity in neurons (pretangles, asterisk) and astrocytic plaques (#) in CBD patients, while c PSP patients
show AT8 immunoreactivity in pretangles (asterisk) and tufted astrocytes (arrowhead). d No AT8 immunoreactivity was detected in control individuals.
Scale bar: 50 μm
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Accumulation of LC3-positive structures in frontal cortex
from patients with taoupathies and colocalization with
hyperphosphorylated tau
Several studies have shown that hyperphoshorylated tau
can be cleared by the autophagy pathway [14, 16, 24, 66]
and accumulation of pathological hyperphosphorylated tau
and p62/SQSTM1 could result from defective autophagy-
lysosomal clearance [35, 68]. To investigate whether the
autophagy system is impaired in human tauopathies, we
analysed the expression of LC3, a well-established autopha-
gosome marker [29], by immunostaining of frontal cortex
sections from controls and patients. In control individ-
uals, we observed diffuse LC3 immunostaining in the
cytoplasm and only rarely detected LC3-positive
puncta (Fig. 3e, i, m). In contrast, in FAD patients
(Fig. 3f, j, n), we observed an increase in LC3-positive
puncta in the perinuclear cytoplasm (arrowheads in
Fig. 3j, n) and in threads (asterisks in Fig. 3j). Interest-
ingly, we also observed a marked increase of LC3-
positive puncta in the cytoplasm of cells in the frontal
cortex of CBD (Fig. 3g, k, o, arrowheads) and PSP pa-
tients (Fig. 3h, l, p, arrowheads). Altogether, these re-
sults suggest that accumulation of autophagic vesicles
is a common feature in patients with tauopathies. In
addition to the LC3-positive puncta in the perinuclear
cytoplasm, we observed strong LC3 immunoreactivity
in places distant from any clearly visible soma in all
three patient groups but not in controls (Fig. 3).
Next we investigated if hyperphosphorylated tau coloca-
lized with LC3 in patients with tauopathies. In FAD pa-
tients, colocalization between hyperphosphorylated tau
(Tau/pS422) and LC3 was found in tangle-like
Fig. 2 The autophagic marker p62/SQSTM1 accumulates and colocalizes with hyperphosphorylated tau in human tauopathies. Double
immunohistochemistry against p62/SQSTM1 (green), hyperphosphorylated tau (Tau/pS422, red) and DAPI (blue) are shown by confocal analysis.
a In control individuals, p62/SQSTM1-positive inclusions are only rarely observed and (e, i) no Tau/pS422 immunoreactivity were detected. b-h
Strong immunoreactivity of p62/SQSTM1 (b-d) and Tau/pS422 (f-h) in post-mortem brain sections from FAD, CBD and PSP patients. j-l Merged
pictures show colocalization between p62/SQSTM1 and Tau/pS422. j In FAD patients, colocalization is shown in neuronal threads (asterisks and
high magnification m) and close to the nucleus (arrowheads and high magnification n). k, o In CBD patients, asterisks indicate colocalization in
threads. l, p In PSP brains, colocalization is detected in threads (asterisks) and in some cell bodies (arrowheads). Scale: 20 μm (10 μm insert)
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structures (arrows in Fig. 3j, n; see also Additional file 2:
Figure S2) and in neuropil threads (asterisks in Fig. 3j and
high magnification Fig. 3n, q). CBD and PSP patients
showed colocalization of hyperphosphorylated tau and
LC3 mainly in threads (asterisks in Fig. 3k, l and high
magnifications in Fig. 3o, r, s), although we cannot exclude
that this is a result of the low levels of hyperphosphory-
lated tau in neuronal soma in CBD and PSP patients.
To confirm the colocalization between hyperpho-
sphorylated tau and LC3, we performed in situ proximity
ligation assay (PLA) analysis, a technique to detect and
quantify protein-protein interaction with high specificity
and sensitivity [64]. We detected significant PLA signals
for hyperphosphorylated tau (AT8) and LC3 in the
frontal cortex of FAD, CBD and PSP cases (Fig. 4b-d),
while no colocalization signal was observed in control
individuals (Fig. 4a). The PLA signal was often observed
in cell bodies (Fig. 4f, asterisk) and in the neuropil
threads (arrowhead) in FAD patients. In contrast, CBD
and PSP patients rarely showed PLA signal in the
Fig. 3 Accumulation of autophagic marker (LC3) and colocalization with hyperphosphorylated tau (Tau/pS422). Double immunofluorescence
analysis on post-mortem tissues against (a-d) Tau/pS422 (red) and (e-h) LC3 (green). j-p Nuclei are stained with DAPI (blue, outlined with a white
dashed line) in the merged pictures. e In control samples, LC3 staining is diffuse in the cytoplasm and LC3-positive dots are rarely observed (high
magnification in (m) of the boxed area in i). j-l Arrowheads (and high magnifications, n-p) indicate cells showing accumulation of LC3 positive
puncta in the perinuclear cytoplasm in FAD, CBD and PSP patients. Asterisks show colocalization in threads. In addition, FAD shows colocalization
in tangle-like structures (j, n, arrows, see also SF. 2). q-s High magnification of the boxed areas in j-l showing colocalization of Tau/pS422 and LC3
in threads, respectively in FAD, CBD and PSP. Scale bars indicate 50 μm (i) and 25 μm (j-l); high magnification 10 μm (m-p) and 5 μm (q-s)
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perinuclear region (Fig. 4g, h, asterisks), and mainly
further away from cell nuclei (Fig. 4g, h, arrowheads),
consistent with the double-immunofluorescence data.
Quantification of the PLA signal (Fig. 4i) showed signifi-
cantly more colocalization of hyperphosphorylated tau
and LC3 in FAD (11.5 ± 2.2 dots/field), CBD (17.2 ± 5.3
dots/field) and PSP (13.9 ± 6.9 dots/field) compared to
control individuals (0.7 ± 1.2 dots/field; p < 0.05 vs FAD,
p < 0.01 vs CBD and p < 0.05 vs PSP). Altogether, our
data suggest that pathological tau is present in LC3-
positive structures in FAD, CBD and PSP human post-
mortem brain.
Accumulation of lysosomal markers and impairment of
lysosomal integrity in tauopathies
The accumulation of autophagic vesicles in AD patients
has been suggested to be a result of defective lysosomal
clearance [37, 39, 70]. To investigate this hypothesis, we
analysed the localisation and the integrity of lysosomes
in frontal cortex of tauopathy patients. First, we analysed
the protein level of the lysosomal-associated membrane
protein 1 (LAMP1), a major lysosomal glycoprotein, by
Western blot. We found significantly higher LAMP1
protein levels in frontal cortex from FAD (AU 0.42 ±
0.09) and CBD (AU 0.38 ± 0.03) compared to control
(AU 0.15 ± 0.062, p < 0.01 vs FAD and p < 0.05 vs CBD,
Fig. 5a-b). Frozen brain tissue for Western blot analysis
was not available from patients with PSP.
Next, we analysed the expression of Cathepsin D (Cat D),
a major lysosomal hydrolase involved in the proteolytic
degradation of proteins in lysosomes, by immunofluores-
cence. In frontal cortex from controls, we observed small
perinuclear Cat D-positive punctate structures, correspond-
ing to lysosomes (Fig. 5j, n, t, asterisks and Additional file
3: Figure S3). In contrast, the Cat D immunoreactivity was
stronger in FAD, CBD and PSP patients compared to con-
trol individuals (Fig. 5g-i and Additional file 3: Figure S3).
Two different patterns of Cat D immunoreactivity were ob-
served: (1) a staining pattern of small vesicular structures,
corresponding to lysosomes (Fig. 5q-s, asterisks) and (2) a
Fig. 4 In situ PLA on human brain tissue confirms colocalization between hyperphosphorylated tau (AT8) and LC3. a-d The white signal shows
the PLA dots in healthy controls and patients, respectively. In merged pictures, PLA staining (red) and DAPI (blue) are shown in FAD, CBD and
PSP. PLA dots are rarely observed in control individuals. e-h High magnification of the boxed area from the merged pictures. Asterisks show PLA
signal close to the nucleus (white dashed line), and arrowheads indicate PLA signal distant from clearly visible cell soma in FAD, CBD and PSP
patients. Scale: 10 μm. i In the graphs PLA signal (number of dots/field) are indicated as Mean value ± S.D. from healthy controls and patients
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Fig. 5 (See legend on next page.)
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diffuse Cat D staining pattern showing a fluorescent
signal throughout the cytoplasm (Fig. 5q-s, arrows,
and Additional file 3: Figure S3), suggesting that Cat D
could have leaked out of the lysosomes (reviewed in
[8, 74, 78]). Taken together the Cat D results suggest
that the lysosomal integrity may be impaired in all
three patient groups.
Finally we analysed the colocalization of hyperpho-
sphorylated tau with Cat D using double immunofluor-
escence. In all three patient groups, we found that Cat
D-positive staining rarely colocalized with hyperpho-
sphorylated tau and only a few cells were immunoreac-
tive for both Tau/pS422 (red) and Cat D (green)
(arrowheads and inset in FAD and PSP, Fig. 5k, m, o, p).
This suggests that hyperphosphorylated tau is not local-
ized to lysosomes which is in line with previous studies in
sporadic AD patients [5, 15].
Discussion
Here we used human post-mortem brain tissue to dem-
onstrate that abnormal accumulation of markers of the
autophagy-lysosomal pathway is a common feature of
different tauopathies. We found that patients with pri-
mary (CBD and PSP) and secondary (early onset FAD)
tauopathies show an abnormal accumulation of the au-
tophagy markers p62/SQSTM1 and LC3, and that both
these markers colocalized with hyperphosphorylated
tau. In FAD patients, hyperphosphorylated tau coloca-
lized with LC3-positive structures and p62/SQSTM1
both in the soma and in neuritic threads, while in
CBD and PSP patients, colocalization was found
mainly in threads. Previous studies have demonstrated
that hyperphosphorylated tau impairs microtubule-
based axonal retrograde transport [27, 44, 46, 49], and
that disruption of microtubule-based vesicle transport,
either by the microtubule-depolymerizing drug vin-
blastine or by deleting the motor-protein dynein, re-
sults in a massive accumulation of autophagosomes in
neurites [7, 28]. Thus, it is tempting to speculate that
the accumulation of hyperphosphorylated tau, p62/
SQSTM1 and LC3 in threads in the tauopathy patients
are, at least partly, due to impaired axonal transport. It
should be noted that in CBD and PSP patients, hyper-
phosphorylated tau is found both in neurons and in
glial cells, and although the autophagy-lysosomal path-
way has been demonstrated to be the main degradative
pathway of tau in neurons, other mechanisms (includ-
ing the ubiquitin-proteasome system) may be involved
in degradation of tau in other cell types such as glia
[32, 67, 68].
Our analysis of lysosomal markers showed increased
protein levels of LAMP1 and Cat D in FAD patients as
well as in patients with primary tauopathies, suggesting
a defective lysosomal clearance which is in line with pre-
vious reports in AD brain [10, 12, 48, 53, 58]. In contrast
to the control cases where Cat D staining was typically
punctate, indicating localization within lysosomes, we
observed diffuse cytoplasmic Cat D immunoreactivity in
the tauopathy patients. Diffuse Cat D staining in the
soma is indicative of lysosomal membrane rupture [1],
and can be induced by oxidative stress [26, 59]. It has
also been reported that tau can interact with lysosomal
membranes and trigger lysosomal permeability in vitro
[68] and that small tau fibrils can bind to lysosomal
membranes resulting in lysosomal damage in a trans-
genic mouse model of AD [15]. Further studies are
needed to determine if there is a leakage of Cat D into
the cytoplasm in human tauopathies, but our data indi-
cate that defective lysosomal integrity is prominent in
FAD, CBD and PSP patients. It should be noted that the
increased LAMP1 levels could be attributable to gliosis
in the tauopathy patients [5, 11, 13].
In recent years, several studies have indicated that
(pharmacological) induction of autophagy can be benefi-
cial for treatment of neurodegenerative diseases, and
increased autophagy has been shown to ameliorate path-
ology in various disease models by enhancing the clear-
ance of intracytoplasmic protein aggregates, including
hyperphosphorylated tau [22, 66]. It is possible that an im-
paired retrograde transport could explain the observed ac-
cumulation of LC3-positive structures containing
hyperphosphorylated tau in threads in tauopathy patients.
On the other hand, our findings from the FAD cases sug-
gest that hyperphosphorylated tau can be transported to
(See figure on previous page.)
Fig. 5 Accumulation of lysosomal markers and diffuse cytoplasmic Cat D immunoreactivity in tauopathies. a Western blot analysis of LAMP1 in
human post-mortem brain (frontal cortex) extracts from control individuals (Ctrl, n = 3), early onset familial AD (FAD, n = 3) and CBD (n = 2). b LAMP1
levels quantified by densitometry and normalized to GAPDH in Ctrl, FAD and CBD. Results are shown as the mean value of arbitrary unit ± S.D (mean
of three independent experiments). c-t Double immunohistochemistry against hyperphosphorylated tau (Tau/pS422, red, c-f) and Cat D (HPA003001,
Sigma-Aldrich) (green, g-j) are shown by confocal analysis. k-n Merged pictures with nuclear staining (DAPI, blue). In FAD, CBD and PSP cases, strong
Cat D-immunoreactivity is present in the soma of the cells in frontal cortex compared to the control. k-m (and high magnification q-s) Distinct
vesicle-like structures (asterisks) and diffuse immunoreactivity (arrows) of Cat D throughout the cell bodies are shown in the pictures. In
addition, in FAD and PSP, arrowheads in k and m and high magnification pictures (o-p) of boxed areas show hyperphosphorylated tau-
positive structures close to Cat D-positive structures. t Brain tissues from control individuals show few Cat D-positive vesicle structures (asterisks). Scale
bars: 50 μm (5 μm high magnification)
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the soma where we observed colocalization with LC3 and
p62/SQSTM1.
Conclusions
In conclusion, our findings give support for an impairment
of the autophagy-lysosomal system in patients with pri-
mary tauopathies as well as in familial AD caused by the
Swedish APP mutation. Although the autophagosomal-
lysosomal clearance pathway is compromised in all three
tauopathies, our observations also indicate that the precise
location of the impairment along this pathway is not neces-
sarily the same. Thus, our study highlights the fact that
therapeutic strategies targeting the autophagosomal-
lysosomal pathway may need to be specifically tailored for
different tauopathies.
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Additional files
Additional file 1: Figure S1. Tau pathology observed with the
Tau/pS422 antibody. a-f Immunofluorescence staining against
hyperphosphorylated tau (Tau/pS422) in human brain samples. Intense
immunoreactivity in FAD, CBD and PSP. a FAD cases show immunoreactivity
in neurofibrillary tangles, pretangles, neuropil threads and dystrophic
neurites. b-c CBD and PSP cases show immunoreactivity in neurons and glial
cells. d-f High magnification of the boxed areas in a-c. Scale bars: 50 μm
(10 μm high magnification) (TIF 3632 kb)
Additional file 2: Figure S2. Colocalization between
hyperphosphorylated tau (Tau/pS422) and LC3 in AD cases. a-d
Double immunofluorescence staining against hyperphosphorylated
tau (a) and LC3 (b) and merge (c) pictures in human brain samples
show colocalization in neurons (NFT-like structures) in FAD samples. d
Superposition of confocal stacks. Scale bar: 10 μm (TIF 25517 kb)
Additional file 3: Figure S3. Diffuse staining pattern of Cathepsin D
(Cat D) (ab6313, Abcam) in tauopathies a-h Merged pictures show
immunofluorescence staining of Cat D (green) and DAPI (nuclear marker,
blue). a-c Diffuse immunoreactivity for Cat D in FAD, CBD and PSP
patients (arrows) and distinct vesicle-like structures (asterisks). d and h
Control samples show Cat D-positive vesicular-like structure (asterisks)
and not diffuse staining. e-h High magnification of the boxed areas in
a-d. Scale bars: 50 μm (20 μm high magnification). (TIF 25515 kb)
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